Atossa Therapeutics Presents Data from 40mg Cohort of Phase
SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and...
Source: globenewswire.com
Steven Quay News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Steven Quay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Steven Quay Today - Breaking & Trending Today
Atossa Therapeutics sets sights on breast cancer trial results after strong 4Q
Atossa Therapeutics Inc (NASDAQ:ATOS) told investors it ended 2023 with $88.5 million in cash and cash equivalents and no debt as it advanced its...
Source: proactiveinvestors.com
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024First patient dosed in new Phase 2 breast cancer prevention studyData from ongoing Phase
Source: eagletribune.com
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announced that the first patient has been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (R
Source: yahoo.com
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innov...
Source: businessinsider.com